荃銀高科(300087.SZ):上半年淨利扭虧為盈至1006.62萬元 擬10派0.5元
格隆匯 8 月 26日丨荃銀高科(300087.SZ)公佈2020年半年度報告,上半年公司實現營業收入5.62億元,較上年同期增長161.35%;實現歸屬於上市公司股東的淨利潤1006.62萬元,同比實現扭虧為盈。主要原因是:(1)種子銷量及訂單糧食業務收入同期增加,毛利增加;(2)公司收到的政府補助較上年同期增加。
公司經本次董事會審議通過的普通股利潤分配預案為:以實施權益分派股權登記日登記的總股本扣除公司回購專户的股份為基數,向全體股東每10股派發現金紅利0.5元(含税),送紅股0股(含税),不以公積金轉增股本。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.